This conference is organised by Elsevier
Abstract submission deadline: 18 September 2020
Early registration deadline: 20 November 2020
International brain stimulation award deadline: 1 June 2020
International brain stimulation early career award deadline: 1 June 2020
International brain stimulation young investigator travel awards deadline: 18 September 2020
Co-Chair: Mark S. George
Editor-in-Chief, Brain Stimulation, Medical University of South Carolina, Charleston, SC, USA
In 1995 Dr. George, a South Carolina native, returned to Charleston and built a campus-wide research brain imaging division and the brain stimulation laboratory in the Department of Psychiatry. As an undergraduate student in philosophy at Davidson College, Dr. George began studying the relationship between mind and brain, or brain/behavior relationships.
View full bio
He has continued this interest throughout his career with a focus on using brain imaging and brain stimulation to understand depression and devise new treatments. He received his medical degree from MUSC in 1985, where he continued with dual residencies in both neurology and psychiatry. He is board certified in both areas.
Following his residency training he worked for one year (1990-91) at the Institute of Neurology, Queen Square, London, England. He then moved to Washington, DC, working in the Intramural National Institute of Mental Health (NIMH). He was one of the first to use functional brain imaging during normal emotions as well as in depression and mania. He has grown the science of brain stimulation, both in terms of how the treatments work in the brain, and in critically evaluating their therapeutic applications, especially in treating depression. He may be unique in being the only living neuroscientist with 2 FDA approved treatments that stem from their work. Transcranial magnetic stimulation (TMS) was FDA approved for treating depression in October, 2008. In June 1998 at MUSC, he also pioneered another new treatment for resistant depression, vagus nerve stimulation (VNS). This was FDA approved in 2006.
He is a world expert in brain stimulation, and depression, and is the editor-in-chief of a new journal he launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has been continuously funded by NIH and other funding agencies since his fellowships. He has received numerous national and international awards. In 2009 US News and World Report named him one of 14 ‘medical pioneers who are not holding back’. He has published over 400 scientific articles or book chapters, and has written or edited 6 books.
Co-Chair: Harold A. Sackeim, PhD
Founding Editor, Brain Stimulation, Columbia University, New York, NY, USA
Dr. Harold A. Sackeim is Professor of Clinical Psychology in Psychiatry and Radiology, College of Physicians and Surgeons, Columbia University. He served as Chief of the Department of Biological Psychiatry at the New York State Psychiatric Institute for 25 years. He is also the founding Editor of the journal, Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation.
View full bio
He received his first B.A. from Columbia College, Columbia University (1972), another B.A. and a M.A. from Magdalen College, Oxford University (1974) and his Ph.D. from the University of Pennsylvania (1977), where he also completed his clinical training in the Department of Psychiatry. He joined the faculty of Columbia University in 1977, where he remains today.
His research has concentrated on the neurobiology and treatment of mood disorders. He has made numerous contributions to the understanding of pathophysiology of major depression and mania through use of brain imaging techniques and by examining the role of lateralization of brain function in normal emotion, neurological disorders, and psychiatric illness. For 30 years, he led the clinical research on electroconvulsive therapy (ECT) at Columbia University and the New York State Psychiatric Institute. This work has identified fundamental factors in this treatment that are responsible for its efficacy and side effects, and has radically altered understanding of both therapeutics and mechanisms of action. This research program has provided compelling evidence regarding the localization of the brain circuits involved in antidepressant effects, and has revamped understanding of the underpinnings of ECT’s effects on mood, behavior, and cognition. Dr. Sackeim is widely credited with transforming the use of this treatment worldwide. Dr. Sackeim has directed programs at the New York State Psychiatric Institute and New York Presbyterian Hospital in the pharmacological treatment of late-life depression, and in the use of Transcranial Magnetic Stimulation (TMS), Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS) and other forms of focal brain stimulation. Dr. Sackeim is the inventor of Magnetic Seizure Therapy (MST), now undergoing clinical trials and has recently developed FEAST (Focal Electrically-Administered Seizure Therapy. Dr. Sackeim introduced functional brain imaging to the medical center at Columbia in 1980, and directed a large group using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to study pathophysiology and treatment effects in mood disorders, anxiety disorders, Lyme disease, substance abuse, Alzheimer’s disease, and normal aging. Other work directed by Dr. Sackeim involved preclinical, primate research on the functional significance of structural brain changes (neurogenesis) induced by different forms of brain stimulation.
Dr. Sackeim is a member of the editorial board of several journals, and has received many national and international awards for his research contributions. These include three Distinguished Investigator Awards from the National Association for Research in Schizophrenia and Depression (NARSAD), a MERIT Award from the National Institute of Mental Health (NIMH), the Joel Elkes International Award from the American College of Neuropsychopharmacology (ACNP), election as Honorary Fellow of the American Psychiatric Association, and the Award for Research Excellence from the New York State Office of Mental Hygiene, Edward Smith Lectureship, National Institute of Psychobiology, Israel, the lifetime achievement award form the EEG and CNS Society, and the NARSAD Maddox Falcone Prize for lifetime achievement in research on affective disorders. He is past President of the Society of Biological Psychiatry and the Association for Research in Nervous and Mental Disease. He has authored more than 425 publications.